Deoxyribonucleic acid and Tubulin beta chain (DNA/TUBB)

Deoxyribonucleic acid (DNA) and Tubulin beta chain represent a dual-target paradigm in oncology designed to enhance cytotoxic effects and overcome drug resistance. DNA is the fundamental molecule of heredity, and its disruption via alkylation or intercalation by therapeutic agents triggers DNA damage responses that lead to cell death [1]. Tubulin beta chain is a vital protein subunit of microtubules, which are essential for the formation of the mitotic spindle during cell division, as well as for intracellular transport and structural integrity [2]. By targeting both DNA and Tubulin beta chain, drugs can simultaneously inhibit DNA replication in the S-phase and disrupt mitosis in the M-phase, providing a synergistic approach to halting the proliferation of aggressive cancer cells [3]. This strategy is often realized through the development of hybrid molecules or combination therapies that aim to provide a more robust clinical response than single-target agents [4]. Such dual-acting agents are particularly useful in treating multi-drug resistant cancers where cells have developed mechanisms to bypass single-pathway inhibition [4]. Clinical examples include agents like estramustine, which combines an estrogenic moiety with a nitrogen mustard to target both microtubule-associated proteins and DNA [5]. However, the complexity of hitting two distinct structural targets necessitates careful management of overlapping toxicities such as myelosuppression and neurotoxicity [6].

Other names

DNA and tubulinDNA/microtubule dual targetDNA-tubulin hybrid target

Dual-action mechanism involving the covalent modification or intercalation of DNA to inhibit replication and transcription, combined with binding to beta-tubulin to disrupt microtubule assembly and spindle formation, leading to cell cycle arrest and apoptosis [3].